OCS
Oculis Holding AG
NASDAQ · Healthcare · Biotechnology · CH
$7.32
+0.41%Oct 19, 2026, 06:00 UTC
Oculis Holding AG completed randomization in the PREDICT-1 registrational trial of licaminlimab, with 176 patients enrolled and two-thirds carrying the TNFR1 genetic variant targeted for enrichment.
Oct 7, 2026, 06:00 UTC
Oculis Holding AG announced plans to highlight licaminlimab at Eyecelerator @ AAO 2026 and partner with Neuro-Ophthalmology Subspecialty Day.
Source:Oct 1, 2026, 06:00 UTC
Oculis joined the National Multiple Sclerosis Society's campaign to end MS, aligning with the campaign's goal to accelerate MS research breakthroughs and improve patients' quality of life.
Source:Sep 17, 2026, 20:05 UTC
A member of Oculis Holding AG's Board of Directors purchased ordinary shares of the company, as disclosed in a notification published on September 17, 2026.
Source:Aug 24, 2026, 08:00 UTC
Oculis Holding AG announced that the first patient has been treated in the PIONEER-1 registrational trial of Privosegtor for optic neuritis.
Source:Aug 10, 2026, 07:01 UTC
Oculis Holding AG signed an asset purchase agreement with Accure Therapeutics to acquire all worldwide development and commercial rights to Privosegtor, terminating their existing license agreement.
Source:Aug 6, 2026, 20:05 UTC
Oculis Holding AG reported its financial results for the second quarter ended June 30, 2026.
Source:Jun 9, 2026, 08:00 UTC
Oculis Holding AG randomized the first patient in the PREDICT-1 registrational trial of Licaminlimab for dry eye disease.
Source:May 31, 2026, 21:05 UTC
Oculis shelves FDA filing for OCS-01 in diabetic macular edema after Phase 3 trials miss key vision goals.
Source: